skip to content

FDA approves Roche’s Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

MediaMedia releases
view all, Media releases

stay updated

get the latest news and updates to your inbox.